Most people assume healthcare money flows only to hospitals. Namit Chugh sees 60 to 70 digital health companies a month and invests in fewer than one in a hundred.
In this episode of The Builders Club Startup Founders Podcast, the W Health Ventures investor breaks down digital health investing in India, from market waves and TAM to the metrics that decide a cheque.
How do VCs approach digital health investing in India? Namit Chugh’s thesis
Namit’s view is that healthcare in India and the US is broken on access, affordability and quality, and that technology is the only lever that can change it at scale. W Health Ventures backs early-stage, tech-enabled healthcare companies in both markets.
He groups the fund’s interests into three areas: vertical care for a specific disease, D2C brands at the edge of health and wellness, and enablers such as lending, insurance, AI and SaaS.
- Money still sits with hospitals. Out-of-pocket spending makes providers the main revenue pool, but digital niches are opening up.
- Venture-backable means exponential. If a market only supports linear growth, Namit suggests bootstrapping instead.
- Healthcare adds its own metrics. Patient feedback, retention and clinical outcomes sit beside CAC, LTV and gross margin.
- Trust drives go-to-market. Digital health is moving toward omni-channel models with a physical presence.
What is W Health Ventures and what does it invest in?
W Health Ventures is a Boston-based venture firm founded by the Wadhwani family, focused on healthcare companies in the US and India. Namit has spent about two years looking at early-stage digital health there, after roughly six years in healthcare consulting and a stint at another fund.
Beyond venture investing, the firm runs a venture studio in India. It incubates companies from scratch where founders are not chasing complex problems, bringing clinical models from the West and adapting them locally.
- Verticalised care: going deep on one disease area, such as diabetes, mental health or cancer care.
- D2C health and wellness: product-led brands with service layers.
- Enablers: lending, health insurance, AI and SaaS.
What waves has Indian healthtech gone through?
Namit describes the first wave, from around 2013 to 2014, as horizontal models in pharmacy and teleconsultation. The bet was a low acquisition cost against a high lifetime value, which turned out to be mostly a distribution play.
From about 2019 to 2020, vertical plays took over, led by chronic conditions with huge addressable markets. He points to diabetes and mental health, each now attracting many startups, as the obvious spaces.
What does he expect next?
He expects founders to look for spaces with no innovation yet. Pain management is his example, since India has very few dedicated pain doctors for its population.
- Niche white spaces that do not yet exist as specialities.
- Omni-channel models, such as small clinics or shop-in-shop formats.
- Models proven in the US, adapted for an out-of-pocket market.
When is a healthcare startup not venture-backable?
Namit says TAM looks large for almost anything in a country of India’s size, so the real question is whether growth can be exponential. VCs have a fiduciary duty to their investors, so a business that grows only two or three times does not justify the risk.
For such businesses he advises friends-and-family money or bootstrapping and building a small profitable company. He adds that TAM is usually a straightforward exercise of population, prevalence and adoption cuts.
What metrics do healthcare investors check before investing?
Namit lists the standard set: revenue growth, CAC, LTV, gross margin, path to profitability, unit economics and product-market fit. He urges founders to track them for their own sake, not just for investors.
Healthcare adds three more, which he treats as a special category.
- Patient feedback. The team speaks to 50 to 100 patients during diligence to understand their experience.
- Retention and repeat usage. Love for the product is what lets a company charge more and protect margins.
- Clinical outcomes. In diabetes, for instance, a reduction in HbA1c should show up in the data.
How does an investor’s day actually work?
Namit says it is less glamorous than writing cheques. Roughly 35 to 40 percent of his time goes to evaluating new deals, 30 to 40 percent to supporting portfolio companies, and the rest to tracking trends in other sectors and countries.
The firm sees about 70 to 80 deals a month, and he says only around 0.9 percent are funded. Cheques run from seed to Series A, with an average first ticket of around 3.5 million dollars, typically at seed-plus stage with an MVP and early traction.
Can healthtech make money in tier-two and tier-three India?
Namit challenges the assumption that smaller towns will not pay. In his portfolio, 60 to 65 percent of users of a diabetes company come from tier two and beyond, and a pregnancy-care company sees order values similar to metros.
He also cites an obesity clinic in Aurangabad where customers pay up to 12,000 rupees for a three-month plan. He is talking about the middle class and above, not the bottom of the pyramid, where healthcare remains a public good.
- Build the right solution and people will pay.
- Expect first-time users who need education about the condition.
- Digital identity under the Ayushman Bharat Digital Mission could improve the sector’s data layer.
Further reading and sources
- W Health Ventures official site
- Ayushman Bharat Digital Mission on Wikipedia
- Wysa official site
- Venture capital on Wikipedia
Frequently asked questions
What stage does W Health Ventures invest at?
According to Namit Chugh, the firm invests from seed to Series A, usually at seed-plus when there is an MVP and early traction. The average first cheque is around 3.5 to 4 million dollars.
What should a healthtech founder research before building?
Talk to patients, doctors and hospitals to confirm the problem is real and large. Check that your solution is clearly better than the status quo, and study how similar models worked abroad, remembering that India is largely out-of-pocket while the US is payer-driven.
When will Indian digital health startups see exits?
Namit said digital health in India is at a nascent stage and that eventual exits such as IPOs are likely five to seven years away. So far there have been few exits beyond some secondary transactions in e-pharmacy.
Conclusion
Namit Chugh’s message to healthtech founders is to pick a problem that is both large and under-served, stay close to patients, and think about margins and clinical outcomes from day one.
If you are building in health, use his checklist before pitching: is the growth exponential, do patients love it, and does it measurably improve outcomes?
Want more conversations like this? Join The Builders Club, our community of 35,000+ founders and CXOs, and explore more episodes of the Startup Founders Podcast.





